FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993179790> ?p ?o ?g. }

• W2993179790 endingPage "350" @default.
• W2993179790 startingPage "350" @default.
• W2993179790 abstract "Introduction: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity characterized by selective growth of lymphoma cells in the lumina of small vessels. IVLBCL has been listed in the WHO classification, which improves recognition of the disease. However, no standard therapy has been established based on the results of prospective studies. We previously reported promising efficacy of rituximab (R)-containing chemotherapy for IVLBCL (JCO 2008) and a high incidence of central nervous system (CNS) recurrence (25% at 3 y) after R-chemotherapy (Lancet Oncol 2009, Cancer Sci 2010). To explore a more effective first-line treatment, we conducted a phase 2 trial of R-CHOP combined with CNS prophylaxis including R-high-dose methotrexate (R-HDMTX) and intrathecal chemotherapy with MTX, cytarabine (Ara-C), and prednisolone (PSL) (IT). Methods: Major inclusion criteria were untreated, histologically confirmed IVLBCL, age 20-79 y, ECOG PS 0-3, and no apparent CNS involvement at diagnosis. Patients received 3 cycles of R-CHOP followed by 2 cycles of R-HDMTX (3.5 g/m2; 2 g/m2 for ≥70 y) every 2 weeks, and 3 additional cycles of R-CHOP. IT (MTX 15 mg, Ara-C 40 mg, PSL 10 mg) was performed twice during the first 3 cycles of R-CHOP and twice during the final 3 cycles of R-CHOP (4 times in total). If patients achieved complete response (CR), they were observed without any therapy until relapse or disease progression. The primary endpoint was 2-y progression-free survival (PFS), and secondary endpoints included 2-y overall survival (OS), CR rate, cumulative incidence of CNS recurrence at 2 y, patterns of progression, and adverse events. The threshold 2-y PFS was estimated to be 35%, with expected 2-y PFS estimated to be 60%. With a statistical power of 90% and a one-sided, type I error of 5%, a projected sample size of 37 was calculated in anticipation of 10% ineligible patients. The trial was registered in the UMIN Clinical Trials Registry (UMIN000005707). Results: 38 IVLBCL patients were enrolled between June 2011 and July 2016. One patient was found to be ineligible after completion of the protocol treatment due to a past history of lymphoma. The protocol treatment was completed in 34 (89%) of 38 patients. The diagnosis of IVLBCL was histologically confirmed by central pathological review in all enrolled patients. The baseline characteristics of the 37 eligible patients were: male sex, 16 (43%); median age, 66 (range 38-78) y; ECOG PS &gt;1, 15 (41%); stage IV, 37 (100%); serum LDH &gt;ULN, 36 (97%); WBC &lt;4,000/μL, 11 (30%); Hgb &lt;11g/dL, 30 (81%); PLT &lt;105/μL, 17 (46%); and IPI HI/H, 33 (89%) patients. The following clinical symptoms were observed before treatment initiation: B symptoms, 30 (81%); hypoxemia, 10 (27%); neurological symptoms, 3 (8%);exanthema, 4 (11%); hepatomegaly, 15 (40%); splenomegaly, 28 (76%); and hemophagocytosis, 8 (22%) patients. In the 37 eligible patients, the CR rate was 84% (95%CI: 68-94%). With a median follow-up of 3.9 (range, 2.0-6.6) y, 2-y PFS was 76% (95%CI: 59-87%), 2-y OS was 92% (95%CI: 77-97%), and the cumulative incidence of CNS recurrence at 2 y was 2.7% (95%CI: 0.2-12%) (Fig. 1). Only one patient had CNS relapse during follow-up. Of all 38 enrolled pts, there were no treatment-related deaths. G4 non-hematological adverse events were febrile neutropenia, hypokalemia, and low blood pressure in one patient each. Major G3 non-hematological toxicities were febrile neutropenia (32%) and hypokalemia (26%). G3 and G4 lymphocytopenia were observed in 95% and 50% and thrombocytopenia in 40% and 24% of patients, respectively. All toxicities were manageable. Conclusion: This phase 2 trial met its primary endpoint and showed favorable outcomes with a low cumulative incidence of CNS recurrence and acceptable toxicity profiles. These results indicate that R-CHOP combined with CNS prophylaxis including R-HDMTX and IT could be a reasonable treatment option for untreated IVLBCL without apparent CNS involvement at diagnosis. Disclosures Shimada: Takeda Pharmaceutical: Honoraria; MSD: Research Funding; Otsuka Pharmaceutical: Research Funding; Janssen Pharmaceutical: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Eisai: Honoraria, Research Funding; Chugai Pharmaceutical: Consultancy, Honoraria; Kyowa Kirin: Honoraria, Research Funding; AstraZeneca: Honoraria. Yamaguchi:Ono Pharmaceutical: Research Funding; Teijin Pharma: Honoraria; MSD: Honoraria; Astrazeneca: Membership on an entity's Board of Directors or advisory committees; Sumitomo Dainippon Pharma: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Astellas Pharma: Research Funding; Sorrento: Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Meiji Seika Kaisha: Honoraria; Kyowa Hakko Kirin: Honoraria, Research Funding; Eisai: Honoraria; Chugai: Honoraria, Research Funding. Atsuta:Chugai Pharmaceutical Co., Ltd.: Honoraria; Kyowa Kirin Co., Ltd: Honoraria; Mochida Pharmaceutical Co. Ltd: Honoraria; Janssen Paharmaceutical K.K.: Honoraria. Matsue:Celgene: Honoraria; Takeda Pharmaceutical Company Limited: Honoraria; Ono Pharmaceutical: Honoraria; Novartis Pharma K.K: Honoraria; Janssen Pharmaceutical K.K.: Honoraria. Kusumoto:Chugai Pharmaceutical Co., Ltd.: Consultancy, Honoraria, Research Funding; Kyowa Kirin Co., Ltd.: Honoraria, Research Funding. Nagai:Eisai: Honoraria, Research Funding; HUYA Bioscience International: Research Funding; AstraZeneca: Honoraria, Research Funding; Takeda Pharmaceutical: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen Pharmaceutical: Honoraria, Research Funding; Ono Pharmaceutical: Honoraria, Research Funding; Zenyaku Kogyo: Honoraria, Research Funding; Sanofi: Honoraria; Otsuka Pharmaceutical: Research Funding; SymBio Pharmaceuticals Limited: Honoraria, Research Funding; Solasia Pharma K.K.: Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding; IQVIA: Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; MSD: Honoraria; Novartis Pharma: Honoraria; Mundi Pharma: Honoraria, Research Funding; Bayer Pharma: Honoraria, Research Funding; AbbVie: Research Funding. Fukuhara:Mundi: Honoraria; Celgene Corporation: Honoraria, Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria; Eisai: Honoraria, Research Funding; Janssen Pharma: Honoraria; Kyowa-Hakko Kirin: Honoraria; Mochida: Honoraria; Nippon Shinkyaku: Honoraria; Ono Pharmaceutical Co., Ltd.: Honoraria; Takeda Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Zenyaku: Honoraria; AbbVie: Research Funding; Bayer: Research Funding; Gilead: Research Funding; Solasia Pharma: Research Funding. Miyazaki:Eisai: Honoraria; Chugai: Honoraria; Kyowa Hakko Kirin: Honoraria, Research Funding; Celgene: Honoraria; Ono Pharmaceutical: Research Funding; Astellas Pharma: Research Funding; Takeda: Honoraria; SymBio Pharmaceuticals: Honoraria; Nippon Shinyaku: Honoraria; Janssen Pharmaceutical: Honoraria. Okamoto:Kyowa Kirin Co., Ltd.: Other: Scholarship donation; Chugai Pharmaceutical Co., Ltd.: Other: Scholarship donation; Takeda Pharmaceutical Co., Ltd.: Other: Scholarship donation; Taiho Pharmaceutical Co., Ltd.: Other: Scholarship donation. Uchida:Eisai: Honoraria. Tsukasaki:Daiichi Sankyo: Consultancy; Kyowa Kirin: Honoraria; Huya: Consultancy, Honoraria, Research Funding; Byer: Research Funding; Mundi Pharma: Honoraria; Ono Pharmaceutical: Consultancy; Eisai: Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Masaki:Tanabe Mitsubishi: Research Funding; Taiho: Research Funding; Kyowa Kirin: Research Funding; Astellas Pharma: Research Funding; Chugai Pharmaceutical: Research Funding; Ono Pharmaceutical: Research Funding; Pfizer: Research Funding; Eisai: Research Funding; Taisho Toyama: Research Funding; Daiichi Sankyo: Research Funding; Teijin: Research Funding; Takeda Pharmaceutical: Research Funding. Kiyoi:Sumitomo Dainippon Pharma Co., Ltd.: Research Funding; Bristol-Myers Squibb: Research Funding; Chugai Pharmaceutical Co., Ltd.: Research Funding; Astellas Pharma Inc.: Honoraria, Research Funding; Takeda Pharmaceutical Co., Ltd.: Research Funding; Zenyaku Kogyo Co., Ltd.: Research Funding; Kyowa Hakko Kirin Co., Ltd.: Research Funding; Otsuka Pharmaceutical Co.,Ltd.: Research Funding; FUJIFILM Corporation: Research Funding; Eisai Co., Ltd.: Research Funding; Nippon Shinyaku Co., Ltd.: Research Funding; Pfizer Japan Inc.: Honoraria; Perseus Proteomics Inc.: Research Funding; Daiichi Sankyo Co., Ltd: Research Funding. Suzuki:Chugai Pharmaceutical Co.,Ltd.: Honoraria; Meiji Seika: Honoraria; Merck Sharp & Dohme: Honoraria; Takeda Pharmaceutical Co., Ltd.: Honoraria; Bristol-Myers Squibb: Honoraria; Kyowa Hakko Kirin: Honoraria; Celgene: Honoraria; Eisai: Honoraria; ONO Pharmaceutical Co., Ltd.: Honoraria; Janssen: Honoraria; AbbVie: Honoraria; Novartis: Honoraria." @default.
• W2993179790 created "2019-12-13" @default.
• W2993179790 creator A5002642944 @default.
• W2993179790 creator A5003738096 @default.
• W2993179790 creator A5006231239 @default.
• W2993179790 creator A5010644978 @default.
• W2993179790 creator A5015382183 @default.
• W2993179790 creator A5017360616 @default.
• W2993179790 creator A5024316557 @default.
• W2993179790 creator A5024413745 @default.
• W2993179790 creator A5025340212 @default.
• W2993179790 creator A5026708269 @default.
• W2993179790 creator A5027289927 @default.
• W2993179790 creator A5037147135 @default.
• W2993179790 creator A5042608347 @default.
• W2993179790 creator A5042777060 @default.
• W2993179790 creator A5046989635 @default.
• W2993179790 creator A5048645583 @default.
• W2993179790 creator A5049465924 @default.
• W2993179790 creator A5051372277 @default.
• W2993179790 creator A5053906265 @default.
• W2993179790 creator A5055192416 @default.
• W2993179790 creator A5055822412 @default.
• W2993179790 creator A5057323751 @default.
• W2993179790 creator A5058184704 @default.
• W2993179790 creator A5058578824 @default.
• W2993179790 creator A5061237838 @default.
• W2993179790 creator A5061361157 @default.
• W2993179790 creator A5061841627 @default.
• W2993179790 creator A5063243902 @default.
• W2993179790 creator A5067816264 @default.
• W2993179790 creator A5068557516 @default.
• W2993179790 creator A5072772886 @default.
• W2993179790 creator A5086056792 @default.
• W2993179790 creator A5088100950 @default.
• W2993179790 creator A5089913354 @default.
• W2993179790 date "2019-11-13" @default.
• W2993179790 modified "2023-10-15" @default.
• W2993179790 title "Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)" @default.
• W2993179790 doi "https://doi.org/10.1182/blood-2019-126798" @default.
• W2993179790 hasPublicationYear "2019" @default.
• W2993179790 type Work @default.
• W2993179790 sameAs 2993179790 @default.
• W2993179790 citedByCount "2" @default.
• W2993179790 countsByYear W29931797902022 @default.
• W2993179790 crossrefType "journal-article" @default.
• W2993179790 hasAuthorship W2993179790A5002642944 @default.
• W2993179790 hasAuthorship W2993179790A5003738096 @default.
• W2993179790 hasAuthorship W2993179790A5006231239 @default.
• W2993179790 hasAuthorship W2993179790A5010644978 @default.
• W2993179790 hasAuthorship W2993179790A5015382183 @default.
• W2993179790 hasAuthorship W2993179790A5017360616 @default.
• W2993179790 hasAuthorship W2993179790A5024316557 @default.
• W2993179790 hasAuthorship W2993179790A5024413745 @default.
• W2993179790 hasAuthorship W2993179790A5025340212 @default.
• W2993179790 hasAuthorship W2993179790A5026708269 @default.
• W2993179790 hasAuthorship W2993179790A5027289927 @default.
• W2993179790 hasAuthorship W2993179790A5037147135 @default.
• W2993179790 hasAuthorship W2993179790A5042608347 @default.
• W2993179790 hasAuthorship W2993179790A5042777060 @default.
• W2993179790 hasAuthorship W2993179790A5046989635 @default.
• W2993179790 hasAuthorship W2993179790A5048645583 @default.
• W2993179790 hasAuthorship W2993179790A5049465924 @default.
• W2993179790 hasAuthorship W2993179790A5051372277 @default.
• W2993179790 hasAuthorship W2993179790A5053906265 @default.
• W2993179790 hasAuthorship W2993179790A5055192416 @default.
• W2993179790 hasAuthorship W2993179790A5055822412 @default.
• W2993179790 hasAuthorship W2993179790A5057323751 @default.
• W2993179790 hasAuthorship W2993179790A5058184704 @default.
• W2993179790 hasAuthorship W2993179790A5058578824 @default.
• W2993179790 hasAuthorship W2993179790A5061237838 @default.
• W2993179790 hasAuthorship W2993179790A5061361157 @default.
• W2993179790 hasAuthorship W2993179790A5061841627 @default.
• W2993179790 hasAuthorship W2993179790A5063243902 @default.
• W2993179790 hasAuthorship W2993179790A5067816264 @default.
• W2993179790 hasAuthorship W2993179790A5068557516 @default.
• W2993179790 hasAuthorship W2993179790A5072772886 @default.
• W2993179790 hasAuthorship W2993179790A5086056792 @default.
• W2993179790 hasAuthorship W2993179790A5088100950 @default.
• W2993179790 hasAuthorship W2993179790A5089913354 @default.
• W2993179790 hasBestOaLocation W29931797901 @default.
• W2993179790 hasConcept C126322002 @default.
• W2993179790 hasConcept C141071460 @default.
• W2993179790 hasConcept C143998085 @default.
• W2993179790 hasConcept C168563851 @default.
• W2993179790 hasConcept C2775965419 @default.
• W2993179790 hasConcept C2776694085 @default.
• W2993179790 hasConcept C2776755627 @default.
• W2993179790 hasConcept C2778336483 @default.
• W2993179790 hasConcept C2779338263 @default.
• W2993179790 hasConcept C2779429289 @default.
• W2993179790 hasConcept C2779725641 @default.
• W2993179790 hasConcept C2779916150 @default.
• W2993179790 hasConcept C2780151071 @default.
• W2993179790 hasConcept C2781059491 @default.
• W2993179790 hasConcept C2992435398 @default.
• W2993179790 hasConcept C31760486 @default.
• W2993179790 hasConcept C71924100 @default.

• next